GLP-1s are forcing a strategic reset across healthcare: Wells Fargo report
GLP-1s are disrupting a healthcare system built around treating obesity-related complications, forcing providers, insurers and investors to rethink where future revenue and growth will come from, according to a new report from Wells Fargo.
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.